M&A
Telix Acquires ITM in $1.65B Radiopharmaceutical Deal
September 21, 2026
Biotech
M&A
Key Facts
Signal Type
M&A
Industry
Biotech
Companies
Telix Pharmaceuticals, Isotope Technologies Munich, Novartis, Curium Pharma, Lantheus
Date
September 21, 2026
Telix Pharmaceuticals announced it is acquiring Isotope Technologies Munich (ITM) for $1.65 billion. The deal, expected to close by the end of 2026, merges Telix's commercial theranostics portfolio—including Illuccix and Pixclara—with ITM's radioisotope manufacturing business and pipeline. ITM generated $273 million in revenue from its manufacturing operations.
The combined entity will be a major player in radiopharmaceuticals, with Telix reporting $803.8 million in 2025 revenue (56% growth) and projecting over $1.3 billion in 2026 combined revenue. ITM's pipeline lead, ITM-11, targets GEP-NETs and received a manufacturing-related CRL from the FDA, with resubmission planned. The deal adds ITM's Munich-based manufacturing and distribution network to Telix's existing infrastructure.
Competitors include Novartis (Pluvicto, Lutathera), Curium Pharma (recently approved Bexlutry, acquiring Lantheus for $8B), and large pharma players like Eli Lilly, AstraZeneca, Sanofi, and Bristol Myers Squibb that have entered radiopharmaceuticals through M&A from 2023–2025.
ITM plans to resubmit its FDA application for ITM-11, which could unlock significant revenue upside if approved. An interim Phase 3 analysis for ITM-11 in aggressive GEP-NETs is expected in the first half of 2027. Telix's clinical pipeline includes three assets in pivotal testing for prostate cancer, recurrent glioblastoma, and kidney cancer. The post-merger integration will require scaling manufacturing, QA, and commercial operations—creating vendor opportunities for software, consulting, and regulatory support services.
Source:
MedCity NewsGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
